Issue link: https://www.e-digitaleditions.com/i/1208415
This section provides information that may be useful in research and development or manufacturing. Content is provided by the organizations listed. No endorsement or preference is intended. Special Section Formulation Development/excipientS This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the organizations listed. No endorsement or preference is intended. Pre-formulation and formulation capabilities Catalent provides a full suite of pre-formulation and formulation capabilities including screening of optimal API forms (polymorph, salt, co-crystal); physicochemi- cal characterization; API compatibility in aqueous, pro- pellant-based and dry powder formulations; API perfor- mance optimization (solubility, viscosity, particle size reduction, droplet size distribution, etc.); nasal and oral inhalation dose forms (single- or multi-dose); and addi- tional GLP and non-GLP development and characteri- zation services. Whether a single service or a turn-key development solution is required, Catalent Inhalation has the capability and expertise to advance product development, from feasibility studies through registra- tion and commercial supply. Catalent US: + 1 888 SOLUTION www.catalent.com/inhalation New milled lactose grades Meggle rounds up its portfolio for dry powder inhala- tion with the new milled lactose grades InhaLac ® 140 and InhaLac ® 150. The two new inhalative lactose grades with specific particle size distributions are charac- terized by the typical flow- and surface-characteristic of milled lactose grades, providing additional tools for the formulator to tune and optimize the performance of DPI products. As middle-sized milled carrier lactose, InhaLac 140 and InhaLac 150 are suitable for use in pul- monary and nasal drug delivery. Meggle Germany: +49 08071 73 476 www.meggle-pharma.com Particle engineering expertise Lonza Pharma & Biotech has extensive particle engi- neering expertise and capabilities for dry powder inhala- tion (DPI) applications. e newly launched Capsugel ® Zephyr™ DPI portfolio is a comprehensive capsule product offering. It addresses the need for highly cus- tomized solutions for pulmonary route delivery meth- ods and is supported by Lonza's inhalation drug devel- opment and particle engineering capabilities, which include micronization and spray drying. is integrated product and service offering enables consistent and opti- mal release performance for inhalation drugs. Lonza Pharma & Biotech US: +1 888 783-6361 www.capsugel.com End-to-end service Recipharm Inhalation Solutions™ offers end-to-end service for inhalation products, from early stage development through commercial manufacturing. With access to specialized equipment and technolo- gies at our pilot facility, our team has the technical capability to work with different devices, combina- tions, APIs and suspension concentrations, as well as assist with the seamless transfer of projects from small- to large-scale production. Recipharm Sweden: +46 8 602 52 00 www.recipharm.com Inhalation February 2020 29